Navigation Links
New Treatment Found For Pancreatic Cancer

A new treatment has been discovered for pancreatic cancer by researchers belonging to Dartmouth-Hitchcock Medical Center, according to the Annals of Surgical Oncology//. As many as half the patients who were studied responded to the therapy which is reported to be a very high figure. The therapy contributes towards reducing the size of the tumors in addition to reducing the risk of the disease recurring. Reducing the size of the tumor helps people to undergo surgery who were formerly categorized as inoperable. As there are very few symptoms in the case of pancreatic cancer, early detection is very difficult. Removing the entire tumor is the only way to treat the disease. The treatment developed by oncologist J. Marc Pipas reduces the size of the tumor by administering radiation and chemotherapy first, after which it can be surgically be removed. As many as 50% of the tumors had shrunk as a result of the treatment. In the case of one patient who was considered inoperable, the tumor had disappeared altogether. As many as 24 patients were treated in the Norris Cotton Cancer Center trial with a high dosage of chemotherapy of gemcitabine and docetaxel followed by a combination of gemcitabine and radiation. Half the tumors shrank after the treatment, according to reports, and in the case of one patient, the tumor disappeared altogether. Seventeen of the patients who were studied, later underwent an operation. No local progression or recurrence were reported among the patients who were treated. (ANI)
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...AUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Phar...maceutical company, today announced that it,has la...antiarrhythmic,indicated for the treatment and pro...llation and hemodynamically unstable ventricular,t...ular heart beat.,Sagent,s amiodarone HCl injection...
(Date:7/25/2008)...LSBAD, Calif., July 25 /PRNewswire/ -- AutoGenomic...ration statement on Form S-1 with the,Securities a...itial public,offering of shares of its common stoc...red, all of which are expected to be offered by,Au...ring, have not yet been,determined., J.P. Morgan ...
(Date:7/25/2008)... New program delivers immediate ... [24-hour telephone access to language interprete...ing multilingual solutions. , ... LLE® http://www.lle-inc.com/index.html [(L...ovider of interpretation, translation, and languag...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3
...ide a bridge to a transplant.Heart failure is char...le to pump blood around the body. Till now, it has...sible - with the only real cure being a transplant...e (LVAD) is a mechanical pump which is used to sup...
...lly to the heart.Improvements in heart disease ris...smoking. It's known that smoking increases the ris...oxide in cigarette smoke,// which raises cholester...ther heart disease risk factors. Each 1% increase ...
...e more likely to have a specific variant of a bloo... tests on 500 men who had died suddenly, many of w... men younger than 55, a gene variant known as HPA-... common than in the general population.// The gen...
...skin could be better than white at fending off fun... James Mackintosh says it could explain why dark s...al environments. A popular theory on why darker sk... skin in others, is that// the extra melanin in da...
Other Medicine News:
(Date:7/23/2008)...TTLE, July 23 /- Sound Pharmaceutical...ication with the FDA for the clinical,testing of a...tion of,chemotherapy induced hearing loss or ototo...005, will be tested in advanced stage lung cancer,...um based chemotherapy.,This marks the second devel...
(Date:7/23/2008)...TTLE, July 23 /- Dendreon C...t expects the Independent Data,Monitoring Committe...lysis,of overall survival relating to the Company,...Carcinoma Treatment, also known as D9902B) clinica... the Company,s investigational,active cellular imm...
(Date:7/22/2008)...est awards under Therapeutics Development Initiati...ions to 23; next deadline January 20,2009, NEW Y... its mission to,speed delivery of transformative t...Michael J. Fox Foundation for Parkinson,s Research...industry research teams. The awards,were granted u...
(Date:7/22/2008)...Geoffrey Allan Will Stress the Importance to Patie...ics Approval Pathway, RICHMOND, Va., July 22 /PRN...) a developer of follow-on biologics and biopharma....D., CEO of Insmed, will present at a,Congressiona...he,significant need for establishing an approval p...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 1Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 2Adult offspring of parents with PTSD have lower cortisol levels 381 1Adult offspring of parents with PTSD have lower cortisol levels 381 24 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 14 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 2American Chemical Societys Weekly Presspac Aug 29 2007 218 1American Chemical Societys Weekly Presspac Aug 29 2007 218 2American Chemical Societys Weekly Presspac Aug 29 2007 218 3American Chemical Societys Weekly Presspac Aug 29 2007 218 4American Chemical Societys Weekly Presspac Aug 29 2007 218 5American Chemical Societys Weekly Presspac Aug 29 2007 218 6American Chemical Societys Weekly Presspac Aug 29 2007 218 7American Chemical Societys Weekly Presspac Aug 29 2007 218 8
...NA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Caland...mpany and a,majority-owned subsidiary of Arrowhead... publication in the Proceedings of the,National Ac...f the,NAS, of the first non-human primate study to... siRNA therapeutic candidate that is a,nanoparticl...
...FIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/...as shown potential to,act as a potent payload in a...o the latest edition of the Handbook of Therapeuti...ews immunotoxins, Susanna,Rybak, Ph.D. summarizes ...ty and potency of ONCONASE improves in a number of...
Other Medicine Technology:Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
The NOW® Malaria Test is a field or laboratory test for the differential diagnosis of a Malaria infection. It is intended for the detection of circulating Plasmodium falciparum (P.f.) antigen
Ultraview 1700 Central Monitor
...tient Care Monitor (PCM) and Central Station provi...PCM extends the cardiac cath or electrophysiology ...ath and/or EP procedures, providing both physiomon...device either standalone or on its own network. W...
...nitoring via the Acuity central station and Welch ...nvert non-monitored beds into centrally monitored ...t both wireless and hardwired monitors and clinica...ities from a community hospital to a teaching inst...
Medicine Products: